CTLA4 and head and neck squamous cell carcinoma: Compared with single use either alone, combined therapy with TH-302 and an anti-CTLA-4 Ab augments CTLA-4 blockade in a head and neck squamous cell carcinoma (HNSCC) model; and further improves the survival of HNSCC patients 19.